OnKure Therapeutics reports a Schedule 13G disclosing beneficial ownership stakes by Acorn-related entities and Anders Hove. The filing shows combined reported holdings of several Acorn entities and Mr. Hove ranging from 1,854,525 shares (4.5%) to 3,924,037 shares (9.5%) as of March 27, 2026. Percentages are calculated on a 41,471,564 share base that includes outstanding shares, a March 27, 2026 private placement, and warrants exercisable subject to a 9.9% blocker.
The cover-page comments note that reported share counts include shares issuable upon exercise of warrants and that certain exercises are limited by the 9.9% Blocker.
Positive
None.
Negative
None.
Insights
Acorn-affiliated funds and an affiliated manager report meaningful passive stakes under a Schedule 13G.
The filing lists distinct holdings for Acorn Bioventures, L.P.; Acorn Bioventures 2, L.P.; related GP entities; and Anders Hove, with reported shares and percentages tied to an aggregate 41,471,564-share base. The counts include shares issuable on warrant exercise, with the 9.9% Blocker constraining immediate exercise.
Cash-flow treatment or planned dispositions are not disclosed; subsequent filings would detail any changes in exercise or voting arrangements.
Filing structure follows beneficial ownership reporting conventions and applies ownership blockers as stated.
The Schedule 13G shows shared voting and dispositive power through GP relationships and managerial roles attributed to Anders Hove. The percentages reference a specific share-count aggregation methodology anchored to prior filings and the March 27, 2026 private placement.
Readers should note the filing treats warrant-derived shares as part of the reported totals but states exercise is subject to the 9.9% Blocker.
"The filing is presented as a Schedule 13G cover and ownership disclosure"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
9.9% Blockerregulatory
"Reporting Persons cannot exercise warrants if beneficial ownership would exceed 9.9%"
shared dispositive powerfinancial
"Rows indicate Shared Dispositive Power of reported shares for Acorn entities"
beneficially ownedregulatory
"Amount beneficially owned: information set forth in Rows (5)-(11) of the cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did Acorn Bioventures report in OnKure (OKUR)?
Acorn Bioventures reported beneficial ownership of 2,069,512 shares (5.0%). The count includes shares issuable upon exercise of warrants and is measured on a 41,471,564 share base used in the filing.
How much does Anders Hove beneficially own in OKUR?
The filing reports 3,924,037 shares (9.5%) beneficially owned by Anders Hove. This figure includes shares issuable upon exercise of warrants as shown on the cover page.
What is the 9.9% Blocker referenced in the OKUR filing?
The 9.9% Blocker prevents the Reporting Persons from exercising warrants if exercise would raise their beneficial ownership above 9.9%. The cover-page percentages reflect this limiter where applicable.
Does the Schedule 13G show voting or dispositive power?
Yes. The filing attributes shared voting and dispositive power for the Acorn entities and states Anders Hove may be deemed to beneficially own those shares in his capacity as manager.
What share base was used to calculate the percentages in the OKUR filing?
Percentages are calculated on a base of 41,471,564 shares, which aggregates prior outstanding shares, a March 27, 2026 private placement, and shares issuable upon reported warrant exercises.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
OnKure Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 Par Value
(Title of Class of Securities)
68277Q105
(CUSIP Number)
03/27/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
ACORN BIOVENTURES, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,854,525.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,854,525.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,854,525.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: 1,854,525 shares of Common Stock (including 144,581 shares of Common Stock issuable upon exercise of warrants)
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
ACORN CAPITAL ADVISORS GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,854,525.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,854,525.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,854,525.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: 1,854,525 shares of Common Stock (including 144,581 shares of Common Stock issuable upon exercise of warrants)
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
ACORN BIOVENTURES 2, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,069,512.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,069,512.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,069,512.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: 2,069,512 shares of Common Stock (including 939,782 shares of Common Stock issuable upon exercise of warrants)
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
Acorn Capital Advisors GP 2, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,069,512.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,069,512.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,069,512.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: 2,069,512 shares of Common Stock (including 939,782 shares of Common Stock issuable upon exercise of warrants)
SCHEDULE 13G
CUSIP Number(s):
68277Q105
1
Names of Reporting Persons
Anders Hove
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,924,037.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,924,037.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,924,037.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.5 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: 3,924,037 shares of Common Stock (including 1,084,363 shares of Common Stock issuable upon exercise of warrants)
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
OnKure Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, COLORADO, 80301.
Item 2.
(a)
Name of person filing:
Acorn Bioventures, L.P.
Acorn Capital Advisors GP, LLC
Acorn Bioventures 2, L.P.
Acorn Capital Advisors GP2, LLC
Anders Hove
(b)
Address or principal business office or, if none, residence:
420 Lexington Avenue, Suite 2626, New York, New York 10170
(c)
Citizenship:
Acorn Bioventures, L.P. and Acorn Bioventures 2 L.P. are both Delaware limited partnerships. Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC are both Delaware limited liability companies. Anders Hove is a citizen of the United States of America.
(d)
Title of class of securities:
Common Stock, $0.0001 Par Value
(e)
CUSIP Number(s):
68277Q105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
(b)
Percent of class:
The percentages set forth herein as of March 27, 2026 are calculated based upon 41,471,564, which is the sum of (i) 13,673,565 shares of Common Stock outstanding as of March 12, 2025 as reported in the Company?s Annual Report on Form 10-K for the period ended December 31, 2025 and filed with the Securities and Exchange Commission on March 12, 2025, (ii) 26,713,636 shares of Common Stock issued in the Company?s private placement described in the Company?s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2026, and (iii) 1,084,363 shares of Common Stock representing the total Shares upon exercise of the Filers' warrants, and assumes the exercise of the reported warrants subject to the 9.9% Blocker (as defined below).
Pursuant to the terms of certain of the reported warrants, the Reporting Persons cannot exercise such warrants if the Reporting Persons would beneficially own, after such exercise, more than 9.9% of the outstanding shares of Common Stock (the "9.9% Blocker"). The percentage and the number of shares of Common Stock set forth on the cover page and the footnote of the cover page for each Reporting Person give effect to the Blockers, except that such percentages and such numbers of shares of Common Stock in the cases of Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P. and Acorn Capital Advisors GP2, LLC, each reflect the exercise of the full amount of warrants exercisable by all the Reporting Persons in the aggregate; however, the ability to exercise such warrants by any Reporting Person at any given time is subject to the Blockers which applies to the beneficial ownership of the Reporting Persons in the aggregate.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Acorn Capital Advisors GP, LLC is the General Partner of Acorn Bioventures, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures, L.P. Acorn Capital Advisors GP 2, LLC is the General Partner of Acorn Bioventures 2, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures 2, L.P.
(ii) Shared power to vote or to direct the vote:
Anders Hove, in his capacity as Manager of each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, may be deemed to beneficially own the shares beneficially owned by each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.
(iii) Sole power to dispose or to direct the disposition of:
NA
(iv) Shared power to dispose or to direct the disposition of:
NA
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
